DeepMed Research

M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Combination Chemotherapy in Treating Children With Astrocytomas and Primitive Neuroectodermal Tumors

Phase 2

Completed

Conditions: Brain and Central Nervous System Tumors

Interventions: Drug: MOPP Regimen
Drug: Leucovorin Calcium
Drug: Mechlorethamine Hydrochloride
Drug: Methotrexate
Drug: Prednisone
Drug: Procarbazine Hydrochloride
Drug: Vincristine Sulfate
Procedure: Conventional Surgery

First Posted Date: 2004-04-22

Last Posted Date: 2013-02-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 4

Registration Number: NCT00002463

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases

Phase 2

Completed

Conditions: Metastatic Cancer
Prostate Cancer

Interventions: Drug: Doxorubicin hydrochloride
Drug: Goserelin acetate
Drug: Leuprolide acetate
Drug: Zoledronic acid
Procedure: orchiectomy
Radiation: strontium chloride Sr

First Posted Date: 2004-04-08

Last Posted Date: 2016-11-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 80

Registration Number: NCT00081159

Locations: 🇺🇸
M.D. Anderson Cancer Center at Orlando, Orlando, Florida, United States
🇺🇸
M.D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
🇺🇸
CCOP - Marshfield Clinic Research Foundation, Marshfield, Wisconsin, United States

and more 1 locations

Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the Urothelium

Phase 2

Completed

Conditions: Bladder Cancer
Transitional Cell Cancer of the Renal Pelvis and Ureter
Urethral Cancer

First Posted Date: 2004-04-08

Last Posted Date: 2012-10-22

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 65

Registration Number: NCT00080795

Locations: 🇺🇸
M.D. Anderson Cancer Center at University of Texas, Houston, Texas, United States

Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases

Phase 2

Completed

Conditions: Metastatic Cancer
Prostate Cancer

Interventions: Drug: Docetaxel
Drug: Imatinib Mesylate

First Posted Date: 2004-04-08

Last Posted Date: 2012-10-12

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 116

Registration Number: NCT00080678

Locations: 🇺🇸
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸
M.D. Anderson Cancer Center at University of Texas, Houston, Texas, United States

Nerve-Sparing Radical Prostatectomy With or Without Nerve Grafting Followed by Standard Therapy for Erectile Dysfunction in Treating Patients With Localized Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Alprostadil (E1)
Drug: Papaverine
Drug: Phentolamine mesylate
Drug: Sildenafil citrate
Procedure: conventional surgery

First Posted Date: 2004-04-08

Last Posted Date: 2012-07-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 111

Registration Number: NCT00080808

Locations: 🇺🇸
M.D. Anderson Cancer Center at University of Texas, Houston, Texas, United States

Doxorubicin and Strontium-89 With or Without Celecoxib in Treating Patients With Progressive Androgen-Independent Prostate Cancer and Bone Metastases

Phase 2

Terminated

Conditions: Prostate Cancer
Metastatic Cancer

Interventions: Drug: Celecoxib
Drug: Doxorubicin Hydrochloride
Radiation: Strontium chloride Sr 89

First Posted Date: 2004-04-08

Last Posted Date: 2018-10-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 14

Registration Number: NCT00080782

Locations: 🇺🇸
M.D. Anderson Cancer Center at University of Texas, Houston, Texas, United States

Arsenic Trioxide in Treating Patients With Refractory or Relapsed Chronic Lymphocytic Leukemia

Phase 2

Withdrawn

Conditions: Leukemia

First Posted Date: 2004-03-25

Last Posted Date: 2012-10-10

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT00006090

Dolastatin 10 in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia

Phase 1

Completed

Conditions: Leukemia
Myelodysplastic Syndromes

Interventions: Drug: Dolastatin 10

First Posted Date: 2004-03-23

Last Posted Date: 2018-10-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT00003693

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Radiation Therapy Plus Doxorubicin in Treating Patients With Resectable Primary or Recurrent Retroperitoneal Soft Tissue Sarcoma

Phase 1

Completed

Conditions: Sarcoma

Interventions: Drug: Doxorubicin hydrochloride (DOX)
Procedure: Conventional surgery
Radiation: Intraoperative radiation therapy (IORT)
Radiation: Radiation Therapy (RT)

First Posted Date: 2004-03-23

Last Posted Date: 2012-07-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 36

Registration Number: NCT00004123

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Arsenic Trioxide in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Has Not Responded to Previous Treatment

Phase 2

Withdrawn

Conditions: Leukemia

First Posted Date: 2004-03-16

Last Posted Date: 2018-11-14

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT00006091

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy